Prognostic assessment in patients with newly diagnosed small cell lung cancer brain metastases: results from a real-life cohort.

ABSTRACT:

Purposes

Brain metastases (BM) are a frequent complication in small cell lung cancer (SCLC), resulting in a reduced survival prognosis. Precise prognostic assessment is an important foundation for treatment decisions and clinical trial planning.

Methods

Patients with newly diagnosed SCLC BM were identified from the Vienna Brain Metastasis Registry and evaluated concerning prognostic factors.

Results

489 patients (male 62.2%, female 37.8%; median age 61 years) were included. Neurological symptoms were present in 297/489 (60.7%) patients. A- to oligosymptomatic patients (5 vs. 9 months, p = 0.030) as well as patients with synchronous diagnosis of BM and primary tumor (5 vs. 9 months, p = 0.008) presented with improved overall survival (OS) prognosis. RPA (HR 1.66; 95% C

SUBMITTER: Steindl A 

PROVIDER: S-EPMC6775039 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature